BR112020004935A8 - Composição farmacêutica compreendendo um anticorpo que se liga especificamente a n-terminal de lisil-trna sintetase como princípio ativo para prevenção ou tratamento de doença relacionada com migração celular - Google Patents
Composição farmacêutica compreendendo um anticorpo que se liga especificamente a n-terminal de lisil-trna sintetase como princípio ativo para prevenção ou tratamento de doença relacionada com migração celularInfo
- Publication number
- BR112020004935A8 BR112020004935A8 BR112020004935A BR112020004935A BR112020004935A8 BR 112020004935 A8 BR112020004935 A8 BR 112020004935A8 BR 112020004935 A BR112020004935 A BR 112020004935A BR 112020004935 A BR112020004935 A BR 112020004935A BR 112020004935 A8 BR112020004935 A8 BR 112020004935A8
- Authority
- BR
- Brazil
- Prior art keywords
- antibody
- lysyl
- prevention
- pharmaceutical composition
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5029—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on cell motility
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/9015—Ligases (6)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Food Science & Technology (AREA)
- Toxicology (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Analytical Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20170118917 | 2017-09-15 | ||
| PCT/KR2018/010903 WO2019054819A1 (ko) | 2017-09-15 | 2018-09-17 | 라이실 tRNA 합성효소 N-말단에 특이적으로 결합하는 항체를 유효성분으로 포함하는 면역세포 이동 관련 질환의 예방 또는 치료용 약학적 조성물 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112020004935A2 BR112020004935A2 (pt) | 2022-04-19 |
| BR112020004935A8 true BR112020004935A8 (pt) | 2022-07-05 |
Family
ID=65723723
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112020004935A BR112020004935A8 (pt) | 2017-09-15 | 2018-09-17 | Composição farmacêutica compreendendo um anticorpo que se liga especificamente a n-terminal de lisil-trna sintetase como princípio ativo para prevenção ou tratamento de doença relacionada com migração celular |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US11965038B2 (https=) |
| EP (1) | EP3682898A4 (https=) |
| JP (1) | JP7511241B2 (https=) |
| KR (1) | KR102163465B1 (https=) |
| CN (1) | CN111629752B (https=) |
| AU (1) | AU2018332491B2 (https=) |
| BR (1) | BR112020004935A8 (https=) |
| CA (1) | CA3084461C (https=) |
| RU (1) | RU2749591C1 (https=) |
| WO (1) | WO2019054819A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112019020166A2 (pt) | 2017-03-27 | 2020-06-30 | Medicinal Bioconvergence Research Center | anticorpo que se liga especificamente a região n-terminal de lisil-trna sintetase exposta na membrana celular |
| CA3084461C (en) | 2017-09-15 | 2025-06-17 | Zymedi Co., Ltd. | PHARMACEUTICAL COMPOSITION COMPRISING AN ANTIBODY THAT BINDS SPECIFICALLY TO THE N-TERMINAL END OF LYSYL TRANSFER RIBONUCLE ACID (NTRNA) SYNTHETASE AS AN ACTIVE INGREDIENT FOR THE PREVENTION OR TREATMENT OF A DISEASE RELATED TO IMMUNE CELL MIGRATION |
| WO2020060156A1 (ko) * | 2018-09-17 | 2020-03-26 | 재단법인 의약바이오컨버젼스연구단 | 세포 외막에 노출되는 라이실-tRNA 합성효소 N-말단 영역에 특이적으로 결합하는 항체 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9928136D0 (en) * | 1999-11-29 | 2000-01-26 | Rose Marlene L | Organ rejection and associated conditions |
| KR100961392B1 (ko) | 2008-04-15 | 2010-06-07 | 이화여자대학교 산학협력단 | 항체 파지 표면제시 라이브러리 제조방법, 상기 방법에의해 제조된 항체 파지 표면제시 라이브러리, 상기 항체파지 표면제시 라이브러리 유전자를 포함한 파지미드 벡터 |
| RU2465330C1 (ru) * | 2008-08-18 | 2012-10-27 | Сеул Нэшнл Юниверсити Индастри Фаундейшн | СПОСОБ ИНГИБИРОВАНИЯ МЕТАСТАЗИРОВАНИЯ ЗЛОКАЧЕСТВЕННОЙ ОПУХОЛИ ИЛИ МИГРАЦИИ ЗЛОКАЧЕСТВЕННЫХ КЛЕТОК ПОСРЕДСТВОМ СНИЖЕНИЯ КЛЕТОЧНОГО УРОВНЯ ЛИЗИЛ-тРНК-СИНТЕТАЗЫ (ВАРИАНТЫ), КОМПОЗИЦИЯ И ПРИМЕНЕНИЕ ВЕКТОРА ЭКСПРЕССИИ ИЛИ АНТИТЕЛА ПРОТИВ KRS ДЛЯ ИНГИБИРОВАНИЯ МЕТАСТАЗИРОВАНИЯ ЗЛОКАЧЕСТВЕННОЙ ОПУХОЛИ ИЛИ МИГРАЦИИ ЗЛОКАЧЕСТВЕННЫХ КЛЕТОК |
| AU2008360729A1 (en) | 2008-08-18 | 2010-02-25 | Seoul National University Industry Foundation | Method for controlling cancer metastasis or cancer cell migration by modulating the cellular level of lysyl tRNA synthetase |
| KR101009501B1 (ko) * | 2008-10-10 | 2011-01-18 | 서울대학교산학협력단 | 항-라이실 티알엔에이 합성효소 항체 및 항-라미닌 수용체 항체를 유효성분으로 포함하는 암 진단용 조성물 |
| US9127268B2 (en) * | 2009-12-11 | 2015-09-08 | Atyr Pharma, Inc. | Aminoacyl tRNA synthetases for modulating inflammation |
| CA2800281C (en) * | 2010-06-01 | 2021-01-12 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of lysyl-trna synthetases |
| JP2017502672A (ja) | 2013-12-30 | 2017-01-26 | メディシナル バイオコンバージェンス リサーチ センター | 抗ｋｒｓモノクロナル抗体及びこれの用途 |
| US11111396B2 (en) | 2014-10-17 | 2021-09-07 | C3 Nano, Inc. | Transparent films with control of light hue using nanoscale colorants |
| US10050713B2 (en) | 2015-03-02 | 2018-08-14 | Futurewei Technologies, Inc. | Optical transceiver using duplex media, self-homodyne detection (SHD), coherent detection, and uncooled laser |
| KR20180069146A (ko) | 2016-12-14 | 2018-06-25 | 만도헬라일렉트로닉스(주) | 주차 조향 보조 시스템 및 그 제어방법 |
| BR112019020166A2 (pt) | 2017-03-27 | 2020-06-30 | Medicinal Bioconvergence Research Center | anticorpo que se liga especificamente a região n-terminal de lisil-trna sintetase exposta na membrana celular |
| CA3084461C (en) * | 2017-09-15 | 2025-06-17 | Zymedi Co., Ltd. | PHARMACEUTICAL COMPOSITION COMPRISING AN ANTIBODY THAT BINDS SPECIFICALLY TO THE N-TERMINAL END OF LYSYL TRANSFER RIBONUCLE ACID (NTRNA) SYNTHETASE AS AN ACTIVE INGREDIENT FOR THE PREVENTION OR TREATMENT OF A DISEASE RELATED TO IMMUNE CELL MIGRATION |
-
2018
- 2018-09-17 CA CA3084461A patent/CA3084461C/en active Active
- 2018-09-17 KR KR1020180111060A patent/KR102163465B1/ko active Active
- 2018-09-17 JP JP2020515025A patent/JP7511241B2/ja active Active
- 2018-09-17 AU AU2018332491A patent/AU2018332491B2/en active Active
- 2018-09-17 US US16/646,240 patent/US11965038B2/en active Active
- 2018-09-17 WO PCT/KR2018/010903 patent/WO2019054819A1/ko not_active Ceased
- 2018-09-17 CN CN201880074372.5A patent/CN111629752B/zh active Active
- 2018-09-17 BR BR112020004935A patent/BR112020004935A8/pt unknown
- 2018-09-17 EP EP18856914.9A patent/EP3682898A4/en active Pending
- 2018-09-17 RU RU2020113539A patent/RU2749591C1/ru active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2018332491B2 (en) | 2022-04-14 |
| CN111629752B (zh) | 2024-03-29 |
| KR102163465B1 (ko) | 2020-10-07 |
| CA3084461A1 (en) | 2019-03-21 |
| CA3084461C (en) | 2025-06-17 |
| US20210070880A1 (en) | 2021-03-11 |
| EP3682898A4 (en) | 2021-09-29 |
| BR112020004935A2 (pt) | 2022-04-19 |
| CN111629752A (zh) | 2020-09-04 |
| RU2749591C1 (ru) | 2021-06-15 |
| EP3682898A1 (en) | 2020-07-22 |
| WO2019054819A1 (ko) | 2019-03-21 |
| KR20190031189A (ko) | 2019-03-25 |
| AU2018332491A1 (en) | 2020-04-30 |
| US11965038B2 (en) | 2024-04-23 |
| JP2020534273A (ja) | 2020-11-26 |
| JP7511241B2 (ja) | 2024-07-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112018017172A2 (pt) | anticorpos monoclonais anti-alfa-sinucleína para prevenção da agregação de tau | |
| CL2020001762A1 (es) | Formas cristalinas del derivado de 4-pirimidinsulfamida de aprocitentán. (divisional solicitud 201902464) | |
| BR112012018947B8 (pt) | anticorpo anti-caprin-1 monoclonal, composição farmacêutica, combinação farmacêutica e usos de uma composição farmacêutica, de um anticorpo e de uma combinação farmacêutica | |
| BR112014021102A2 (pt) | Anticorpo, composição farmacêutica, droga de combinação, dna, método de tratamento e uso de anticorpo | |
| BR112012018951C8 (pt) | anticorpo monoclonal, composição farmacêutica, combinação farmacêutica, uso de um anticorpo, uso de uma composição farmacêutica e uso de uma combinação farmacêutica | |
| CL2020002012A1 (es) | Formulaciones de anticuerpos humanos anti-rankl y métodos de uso de estas. (divisional solicitud 201903032) | |
| BR112017003419A2 (pt) | formulação de anticorpo anti-il-4r-alfa estável | |
| BR112015019066A2 (pt) | Anticorpos humanos para proteína f do vírus respiratório sincicial e métodos de uso dos mesmos | |
| CL2017000201A1 (es) | Composiciones y métodos de uso para tratar trastornos metabólicos | |
| NZ743964A (en) | Aqueous pharmaceutical formulation comprising anti-pd-1 antibody avelumab | |
| BR112021019262A2 (pt) | Uso de ciclo-his-pro (chp) para prevenir, atenuar ou tratar fibrose | |
| MX391339B (es) | Composicion farmaceutica que comprende selexipag. | |
| BR112018004532A2 (pt) | uso de akkermansia pasteurizado para o tratamento de distúrbios metabólicos | |
| BR122020001787A8 (pt) | Conjugado de anticorpo-agente ativo, seus métodos de preparação, sua composição e seu uso | |
| BR112015018104A2 (pt) | polipeptídeos de gdf15 modificados, seu uso, composições compreendendo os mesmos e recipiente estéril compreendendo as referidas composições | |
| BR112016002614A8 (pt) | Imunocitoquina, ácido nucleico, vetor, célula hospedeira e composição farmacêutica | |
| BR112014028633A8 (pt) | tratamento de amd usando sflt-1 de aav | |
| BR112019008417A2 (pt) | compostos de peptídeo tirosina-tirosina cíclico acoplados a anticorpo como moduladores de receptores de neuropeptídeo y | |
| BR112019017393A2 (pt) | formulações de evolocumab de baixa viscosidade, alta concentração e métodos para produzir as mesmas | |
| BR112017019343A2 (pt) | uso de composições contendo peptídeo inibidor de mk2 para tratamento de câncer de pulmão de células não pequenas com as mesmas | |
| BR112020004935A8 (pt) | Composição farmacêutica compreendendo um anticorpo que se liga especificamente a n-terminal de lisil-trna sintetase como princípio ativo para prevenção ou tratamento de doença relacionada com migração celular | |
| BR112023020450A2 (pt) | Anticorpos anti-cd19 e estruturas car-t | |
| BR112017013453A2 (pt) | novo peptídeo inibidor de pi3ky para o tratamento de doenças do sistema respiratório | |
| CO2020004801A2 (es) | Uso de suplementos de aminoácidos para mejorar la síntesis de proteínas musculares | |
| MX2021008941A (es) | Moduladores gpr35. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B12F | Other appeals [chapter 12.6 patent gazette] | ||
| B25A | Requested transfer of rights approved |
Owner name: BIOCONTAC CO., LTD. (KR) |
|
| B25A | Requested transfer of rights approved |
Owner name: ZYMEDI CO., LTD. (KR) |
|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |